<DOC>
	<DOCNO>NCT01366664</DOCNO>
	<brief_summary>The purpose study ass pharmacodynamics ( action effect drug body ) , pharmacokinetics ( blood level ) , safety , tolerability dapoxetine 60 mg concomitantly administer participant take terazosin .</brief_summary>
	<brief_title>A Pharmacodynamic Study Dapoxetine Concomitantly Administered Participants Taking Terazosin</brief_title>
	<detailed_description>This multiple-center , randomize ( participant assign study drug chance ) , multiple-dose , double-blind ( neither physician participant know treatment assign ) , placebo ( inactive substance compare drug test whether drug real effect clinical trial ) -controlled , 2-period crossover ( participant may receive different intervention sequentially trial ) study assess pharmacodynamics , pharmacokinetics , safety , tolerability dapoxetine concomitantly administer adult male participant stable dose terazosin doxazosin least 6 week . Study drug use terazosin ( drug give treatment hypertension benign prostatic hyperplasia ) dapoxetine ( new drug study treatment premature ejaculation ) . This study consist screen phase follow double-blind , placebo-controlled treatment phase consist 2 treatment period . Participants remain prescribed dose terazosin participant take doxazosin convert terazosin use protocol-defined dose conversion ( include assessment control urinary symptom risk urinary retention ) . Participants administer concomitant ( time ) dapoxetine placebo daily . Blood sample pharmacodynamic pharmacokinetic measurement collect select time study . Safety monitor . The total duration study participation approximately 49 day . Participants remain prescribed dose terazosin ( 2 10 mg take daily mouth ) administer daily mouth concomitant dapoxetine 60 mg placebo dose 2 treatment period ( 7 day duration conduct study center ) . A period 14 day separate treatment period .</detailed_description>
	<mesh_term>Terazosin</mesh_term>
	<mesh_term>Prazosin</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>On stable regimen terazosin ( 2 10 mg ) doxazosin ( 2 8 mg ) take daily least 6 week treatment hypertension benign prostatic hyperplasia body mass index 18 35 kg/mÂ² , inclusive body weight less 50 kg supine ( lay ) blood pressure measurements 90 150 mmHg , inclusive , diastolic blood pressure measurements high 95 mmHg . History current clinically significant illness illness investigator considers exclude study participant could interfere interpretation study result symptomatic orthostatic hypotension ( decrease &gt; =20 mm Hg systolic blood pressure measure 2 3 minute change supine ( lay ) stand position ) take medication know cause orthostatic hypotension , terazosin , take 2 antihypertensive medication take antihypertensive medication exclude .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Premature Ejaculation</keyword>
	<keyword>Selective Serotonin Reuptake Inhibitor</keyword>
	<keyword>Dapoxetine</keyword>
	<keyword>PRILIGY</keyword>
	<keyword>Terazosin</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>